Kwangdong to market Apthera's breast cancer product NeuVax in Korea

Published: 2009-06-16 06:56:00

Updated: 2009-06-16 06:56:00

Kwangdong Pharm said it has recently entered into a commercial license agreement with the U.S. based Apthera, Inc. for use of Apthera’s NeuVax, a peptide-based cancer immunotherapy product.

Under the agreement, Kwangdong will receive a license to sell NeuVax in Korea for the treatment of early...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK